Observational Study on How Long-term Psychiatric Medication Affects Eye Movements Using the Gaize VR Device

What this Trial Is About

This research aims to evaluate how long-term use of psychotropic medications affects eye movement patterns. It investigates whether the Gaize VR headset, using Drug Recognition Expert DRE testing protocols, can accurately detect specific eye movements linked to psychiatric medication use. The study addresses the need for improved monitoring of visual and eye movement side effects often seen with long-term psychiatric drug use, which traditional methods may miss or assess subjectively. Participants include individuals taking prescribed psychotropic medications for over three months and a control group not using such medications but matched by age and sex. The Gaize VR device will be used in a controlled virtual environment to measure eye movements objectively. Participants will undergo one day of ophthalmic data collection using this technology to assess eye movement patterns. During the study, participants will be recruited through psychiatrists and community outreach. They will provide informed consent and be screened based on specific inclusion and exclusion criteria. Researchers will collect detailed eye movement data to understand the impact of psychiatric medications better. The study runs from April 2024 to August 2028, involving careful monitoring and data collection in a virtual reality setting.

Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device